Gatumu Margaret K, Skarstein Kathrine, Papandile Adrian, Browning Jeffrey L, Fava Roy A, Bolstad Anne Isine
Section for Pathology, The Gade Institute, University of Bergen, Haukeland University Hospital, Jonas Lies vei 65, N-5021 Bergen, Norway.
Arthritis Res Ther. 2009;11(1):R24. doi: 10.1186/ar2617. Epub 2009 Feb 18.
The lymphotoxin-beta receptor (LTbetaR) pathway is important in the development and maintenance of lymphoid structures. Blocking this pathway has proven beneficial in murine models of autoimmune diseases such as diabetes and rheumatoid arthritis. The aim of this study was to determine the effects of LTbetaR pathway blockade on Sjögren syndrome (SS)-like salivary gland disease in non-obese diabetic (NOD) mice.
The course of SS-like disease was followed in NOD mice that were given lymphotoxin-beta receptor-immunoglobulin fusion protein (LTbetaR-Ig) starting at 9 weeks of age. Treatment was given as a single weekly dose for 3, 7, or 10 weeks. Age-matched NOD mice treated with mouse monoclonal IgG1, or not treated at all, were used as controls. The severity of inflammation, cellular composition, and lymphoid neogenesis in the submandibular glands were determined by immunohistochemistry. Mandibular lymph nodes were also studied. Saliva flow rates were measured, and saliva was analyzed by a multiplex cytokine assay. The salivary glands were analyzed for CXCL13, CCL19, and CCL21 gene expression by quantitative polymerase chain reaction.
Treatment with LTbetaR-Ig prevented the increase in size and number of focal infiltrates normally observed in this SS-like disease. Compared with the controls, the submandibular glands of LTbetaR-Ig-treated mice had fewer and smaller T- and B-cell zones and fewer high endothelial venules per given salivary gland area. Follicular dendritic cell networks were lost in LTbetaR-Ig-treated mice. CCL19 expression was also dramatically inhibited in the salivary gland infiltrates. Draining lymph nodes showed more gradual changes after LTbetaR-Ig treatment. Saliva flow was partially restored in mice treated with 10 LTbetaR-Ig weekly injections, and the saliva cytokine profile of these mice resembled that of mice in the pre-disease state.
Our findings show that blocking the LTbetaR pathway results in ablation of the lymphoid organization in the NOD salivary glands and thus an improvement in salivary gland function.
淋巴毒素-β受体(LTβR)途径在淋巴结构的发育和维持中起重要作用。在糖尿病和类风湿关节炎等自身免疫性疾病的小鼠模型中,阻断该途径已被证明有益。本研究的目的是确定LTβR途径阻断对非肥胖糖尿病(NOD)小鼠干燥综合征(SS)样唾液腺疾病的影响。
从9周龄开始给NOD小鼠注射淋巴毒素-β受体-免疫球蛋白融合蛋白(LTβR-Ig),观察SS样疾病的病程。治疗以每周一次的剂量给药3、7或10周。将年龄匹配的用小鼠单克隆IgG1治疗或未治疗的NOD小鼠作为对照。通过免疫组织化学确定下颌下腺炎症的严重程度、细胞组成和淋巴新生。还研究了下颌淋巴结。测量唾液流速,并通过多重细胞因子测定法分析唾液。通过定量聚合酶链反应分析唾液腺中CXCL13、CCL19和CCL21基因的表达。
用LTβR-Ig治疗可防止在这种SS样疾病中通常观察到的局灶性浸润的大小和数量增加。与对照组相比,用LTβR-Ig治疗的小鼠的下颌下腺在每个给定唾液腺区域中T细胞和B细胞区更少、更小,高内皮静脉更少。在用LTβR-Ig治疗的小鼠中,滤泡树突状细胞网络消失。唾液腺浸润中CCL19的表达也被显著抑制。引流淋巴结在LTβR-Ig治疗后显示出更渐进的变化。每周注射10次LTβR-Ig的小鼠唾液流速部分恢复,这些小鼠的唾液细胞因子谱类似于疾病前期小鼠的谱。
我们的研究结果表明,阻断LTβR途径可导致NOD唾液腺中淋巴组织的消融,从而改善唾液腺功能。